Upcoming Rate Cuts: Seize 6% High-Yield S&P 500 Stocks Today
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 26 2025
0mins
Source: Yahoo Finance
Investing in Dividend Stocks: High-yield dividend stocks are favored by investors for their potential to provide substantial income and enhance total return, especially with an anticipated rate cut by the Federal Reserve in late October.
Importance of Total Return: Dividends have historically contributed about 32% of the total return for the S&P 500, with a study showing that dividend stocks delivered an annualized return of 9.18% over the past 50 years, significantly outperforming non-payers.
Highlighted Companies: Notable high-yield dividend stocks include Alexandria Real Estate Equities (6.99%), Altria Group (6.35%), Pfizer (6.93%), UPS (7.64%), and Verizon (6.71%), each with strong market positions and growth potential.
Market Strategies: Companies like UPS are adjusting their strategies to focus on more profitable segments, while others like Pfizer anticipate stable revenues, indicating a trend towards optimizing operations and maintaining dividend reliability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MO
Wall Street analysts forecast MO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 64.390
Low
57.00
Averages
65.00
High
72.00
Current: 64.390
Low
57.00
Averages
65.00
High
72.00
About MO
Altria Group, Inc. operates a portfolio of tobacco products for United States tobacco consumers aged 21+. Its segments include smokeable products and oral tobacco products. The smokeable products segment consists of combustible cigarettes and machine-made large cigars. The oral tobacco products segment includes moist smokeless tobacco (MST) products and oral nicotine pouches. Its wholly owned subsidiaries include manufacturers of both combustible and smoke-free products. In combustibles, it owns Philip Morris USA Inc. (PM USA), and John Middleton Co. (Middleton), which are cigarette manufacturers. Its smoke-free portfolio includes ownership of U.S. Smokeless Tobacco Company LLC (USSTC), a global MST manufacturer, Helix Innovations LLC (Helix), a manufacturer of oral nicotine pouches, and NJOY, LLC (NJOY), an e-vapor manufacturer with a commercialized product portfolio. The brand portfolios of its operating companies include Marlboro, Black & Mild, Copenhagen, Skoal, on! and NJOY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altria Announces National Expansion of on! PLUS™ Nicotine Pouches
- National Product Expansion: Altria has announced the nationwide launch of on! PLUS™ nicotine pouches starting March 23, 2026, marking a significant milestone for Helix Innovations LLC and addressing the growing demand for smoke-free alternatives among adult consumers.
- FDA Authorized Products: on! PLUS™ is the first nicotine pouch product authorized through the FDA's expedited review program, offering three flavors and two nicotine strengths, demonstrating Altria's commitment to innovation within science-based regulatory frameworks and solidifying its market position.
- Technological Innovation: The product features proprietary NICOSLIK technology and a responsible disposal design, aimed at enhancing user experience and meeting consumer expectations for high-quality products, thereby boosting Altria's competitiveness in the smoke-free product sector.
- Market Strategy: By initiating sales through e-commerce and participating retailers in North Carolina, Florida, and Texas, Altria's strategic positioning lays the groundwork for future market expansion, supporting the company's vision of Moving Beyond Smoking®.
See More
Altria and Eli Lilly See Active Options Trading
- Altria Options Volume: Altria Group Inc experienced options trading volume of 67,403 contracts, equivalent to approximately 6.7 million shares, representing about 66.2% of its average daily trading volume over the past month, indicating strong market interest in the stock.
- High Strike Call Activity: Specifically, the $66 strike call option expiring on March 27, 2026, saw 15,952 contracts traded today, representing around 1.6 million underlying shares, suggesting investor optimism regarding Altria's future performance.
- Eli Lilly Options Trading: Eli Lilly recorded options trading volume of 18,822 contracts, approximately 1.9 million shares, or about 64.7% of its average daily trading volume over the past month, reflecting ongoing investor interest in the company.
- Active Call Options: For Eli Lilly, the $1060 strike call option expiring on April 17, 2026, had a trading volume of 1,337 contracts today, representing about 133,700 underlying shares, indicating market confidence in the company's growth prospects.
See More
Altria Shares Rebound, Ending Six-Day Decline
- Stock Rebound: Altria Group (MO) shares rose 0.84% to $64.93 on Tuesday afternoon, breaking a six-day decline, indicating market expectations for a short-term recovery.
- Market Performance Comparison: Between March 16 and 23, Altria's stock fell approximately 4.7%, while the S&P 500 declined only 1.77%, reflecting its relative weakness in the consumer staples sector.
- Analyst Ratings: According to Seeking Alpha's QuantRating system, Altria is rated as a Hold with a score of 3.31, receiving an A+ for profitability but a D- for growth, highlighting the structural challenges it faces.
- Poor Market Outlook: Analysts noted that Altria is experiencing revenue declines and market share erosion in its core business, particularly with poor sales of its oral tobacco products, making its performance disproportionately weak compared to competitors.
See More
Future and Challenges of the Tobacco Industry
- Industry Resilience: Despite smoking rates in the U.S. peaking decades ago, the tobacco industry remains remarkably resilient, with giants like Altria and Philip Morris consistently paying and raising shareholder dividends, indicating their stability in the market.
- Philip Morris Innovation: Philip Morris's heated tobacco brand, Iqos, launched over a decade ago, now accounts for 41.5% of its total net sales, while Altria still relies almost entirely on combustible products, highlighting its lag in the smoke-free product sector.
- Altria's Challenges: Altria's poor performance in the smoke-free market, particularly its failed Juul investment and the underperformance of its On! brand in the U.S., poses significant risks; if it fails to make meaningful progress in alternative products over the next few years, its cigarette business could face severe pressure.
- Investor Preference: With clear competitive advantages in the smoke-free arena, Philip Morris is favored by investors, as Altria must deliver tangible results outside its core business to remain a viable long-term investment option.
See More
Philip Morris Outshines Altria in Tobacco Industry Future
- Industry Resilience: Despite peak smoking rates in the U.S., the tobacco industry remains resilient, with giants Altria and Philip Morris consistently raising shareholder dividends, indicating strong cash flow and profitability.
- Rise of Smoke-Free Products: Philip Morris's smoke-free products now account for 41.5% of its total net sales, while Altria still heavily relies on combustible products, highlighting a strategic divergence that could impact future market share.
- Competitive Advantages: Philip Morris has successfully ramped up its Iqos heated tobacco brand internationally and acquired leading nicotine pouch brand Zyn, enhancing its competitive position in the smoke-free product sector and signaling long-term growth potential.
- Investor Preference: Given Altria's slow progress in the smoke-free space and its failed Juul investment, investors are more inclined to favor Philip Morris as a long-term hold, reflecting market confidence in its future prospects.
See More
Altria Launches Nationwide Availability of on! PLUS Oral Nicotine Pouch
- Nationwide Launch: Altria announced that its on! PLUS oral nicotine pouch is transitioning from limited regional and e-commerce distribution to nationwide retail availability in the U.S., marking a significant commercialization milestone with products expected to hit stores by March 23.
- Innovative Product Features: on! PLUS is a next-generation, spit-free oral nicotine pouch utilizing proprietary NICOSLIK technology, available in three flavors and two nicotine strengths, providing adult nicotine consumers with a smoke-free, portable alternative to traditional tobacco products.
- FDA-Approved Pioneer: on! PLUS is the first nicotine pouch cleared through the FDA’s expedited review program, with six specific products authorized, including mint, tobacco, and wintergreen flavors in both 6 mg and 9 mg strengths, showcasing Altria's innovative capabilities within regulatory frameworks.
- Strategic Vision: Altria emphasizes that the expansion of on! PLUS aligns with its broader vision of moving beyond smoking, focusing on smoke-free products for adult consumers, reflecting the company's commitment to quality and innovation in meeting the growing market demand.
See More
Altria Announces National Expansion of on! PLUS™ Nicotine Pouches
- National Product Expansion: Altria has announced the nationwide launch of on! PLUS™ nicotine pouches starting March 23, 2026, marking a significant milestone for Helix Innovations LLC and addressing the growing demand for smoke-free alternatives among adult consumers.
- FDA Authorized Products: on! PLUS™ is the first nicotine pouch product authorized through the FDA's expedited review program, offering three flavors and two nicotine strengths, demonstrating Altria's commitment to innovation within science-based regulatory frameworks and solidifying its market position.
- Technological Innovation: The product features proprietary NICOSLIK technology and a responsible disposal design, aimed at enhancing user experience and meeting consumer expectations for high-quality products, thereby boosting Altria's competitiveness in the smoke-free product sector.
- Market Strategy: By initiating sales through e-commerce and participating retailers in North Carolina, Florida, and Texas, Altria's strategic positioning lays the groundwork for future market expansion, supporting the company's vision of Moving Beyond Smoking®.
See More
Altria and Eli Lilly See Active Options Trading
- Altria Options Volume: Altria Group Inc experienced options trading volume of 67,403 contracts, equivalent to approximately 6.7 million shares, representing about 66.2% of its average daily trading volume over the past month, indicating strong market interest in the stock.
- High Strike Call Activity: Specifically, the $66 strike call option expiring on March 27, 2026, saw 15,952 contracts traded today, representing around 1.6 million underlying shares, suggesting investor optimism regarding Altria's future performance.
- Eli Lilly Options Trading: Eli Lilly recorded options trading volume of 18,822 contracts, approximately 1.9 million shares, or about 64.7% of its average daily trading volume over the past month, reflecting ongoing investor interest in the company.
- Active Call Options: For Eli Lilly, the $1060 strike call option expiring on April 17, 2026, had a trading volume of 1,337 contracts today, representing about 133,700 underlying shares, indicating market confidence in the company's growth prospects.
See More
Altria Shares Rebound, Ending Six-Day Decline
- Stock Rebound: Altria Group (MO) shares rose 0.84% to $64.93 on Tuesday afternoon, breaking a six-day decline, indicating market expectations for a short-term recovery.
- Market Performance Comparison: Between March 16 and 23, Altria's stock fell approximately 4.7%, while the S&P 500 declined only 1.77%, reflecting its relative weakness in the consumer staples sector.
- Analyst Ratings: According to Seeking Alpha's QuantRating system, Altria is rated as a Hold with a score of 3.31, receiving an A+ for profitability but a D- for growth, highlighting the structural challenges it faces.
- Poor Market Outlook: Analysts noted that Altria is experiencing revenue declines and market share erosion in its core business, particularly with poor sales of its oral tobacco products, making its performance disproportionately weak compared to competitors.
See More
Future and Challenges of the Tobacco Industry
- Industry Resilience: Despite smoking rates in the U.S. peaking decades ago, the tobacco industry remains remarkably resilient, with giants like Altria and Philip Morris consistently paying and raising shareholder dividends, indicating their stability in the market.
- Philip Morris Innovation: Philip Morris's heated tobacco brand, Iqos, launched over a decade ago, now accounts for 41.5% of its total net sales, while Altria still relies almost entirely on combustible products, highlighting its lag in the smoke-free product sector.
- Altria's Challenges: Altria's poor performance in the smoke-free market, particularly its failed Juul investment and the underperformance of its On! brand in the U.S., poses significant risks; if it fails to make meaningful progress in alternative products over the next few years, its cigarette business could face severe pressure.
- Investor Preference: With clear competitive advantages in the smoke-free arena, Philip Morris is favored by investors, as Altria must deliver tangible results outside its core business to remain a viable long-term investment option.
See More
Philip Morris Outshines Altria in Tobacco Industry Future
- Industry Resilience: Despite peak smoking rates in the U.S., the tobacco industry remains resilient, with giants Altria and Philip Morris consistently raising shareholder dividends, indicating strong cash flow and profitability.
- Rise of Smoke-Free Products: Philip Morris's smoke-free products now account for 41.5% of its total net sales, while Altria still heavily relies on combustible products, highlighting a strategic divergence that could impact future market share.
- Competitive Advantages: Philip Morris has successfully ramped up its Iqos heated tobacco brand internationally and acquired leading nicotine pouch brand Zyn, enhancing its competitive position in the smoke-free product sector and signaling long-term growth potential.
- Investor Preference: Given Altria's slow progress in the smoke-free space and its failed Juul investment, investors are more inclined to favor Philip Morris as a long-term hold, reflecting market confidence in its future prospects.
See More
Altria Launches Nationwide Availability of on! PLUS Oral Nicotine Pouch
- Nationwide Launch: Altria announced that its on! PLUS oral nicotine pouch is transitioning from limited regional and e-commerce distribution to nationwide retail availability in the U.S., marking a significant commercialization milestone with products expected to hit stores by March 23.
- Innovative Product Features: on! PLUS is a next-generation, spit-free oral nicotine pouch utilizing proprietary NICOSLIK technology, available in three flavors and two nicotine strengths, providing adult nicotine consumers with a smoke-free, portable alternative to traditional tobacco products.
- FDA-Approved Pioneer: on! PLUS is the first nicotine pouch cleared through the FDA’s expedited review program, with six specific products authorized, including mint, tobacco, and wintergreen flavors in both 6 mg and 9 mg strengths, showcasing Altria's innovative capabilities within regulatory frameworks.
- Strategic Vision: Altria emphasizes that the expansion of on! PLUS aligns with its broader vision of moving beyond smoking, focusing on smoke-free products for adult consumers, reflecting the company's commitment to quality and innovation in meeting the growing market demand.
See More
